Northwest Biotherapeutics Appoints Pat Sarma as Class II Director
Company Announcements

Northwest Biotherapeutics Appoints Pat Sarma as Class II Director

Northwest Biotherapeutics (NWBO) just unveiled an announcement.

Pat Sarma has been appointed as a Class II director and member of the Audit, Compensation, and Conflicts Committees, effective March 18, 2024. His appointment came with no prior arrangements and is free from any related-party transactions requiring disclosure. As an independent director, Sarma will receive the same compensation as other non-employee directors of the company.

For detailed information about NWBO stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNorthwest Biotherapeutics Addresses Market Rumor Concerns
TheFlyNorthwest Biotherapeutics announces exclusive license from Roswell Park
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App